Modern Strategy for Preclinical Pharmaceutical R&d - Cavalla, David
303,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
152 °P sammeln
  • Gebundenes Buch

The twentieth century has been a great success for modern medicine,and has resulted in the generation of a plethora of drugs to treatmost common illnesses. However, in the light of increasingregulatory demands, spiralling costs and diminishing commercialreturns, the question of how, when, where and whether to conductpharmaceutical R&D has profound implications, and not just forthose within the pharmaceutical industry. In response to these andother dilemmas, the authors define the processes involved in drugresearch, and examine the advantages and disadvantages ofcollaborative methods of drug…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The twentieth century has been a great success for modern medicine,and has resulted in the generation of a plethora of drugs to treatmost common illnesses. However, in the light of increasingregulatory demands, spiralling costs and diminishing commercialreturns, the question of how, when, where and whether to conductpharmaceutical R&D has profound implications, and not just forthose within the pharmaceutical industry. In response to these andother dilemmas, the authors define the processes involved in drugresearch, and examine the advantages and disadvantages ofcollaborative methods of drug research, and examine the roles thatacademia, CROs, small "biotechnology" companies and "researchboutiques," and possibly even the "virtual research company" mightplay as contractors and collaborators.
Autorenporträt
David Cavalla is an expert on secondary uses for existing drugs, or drug repurposing. He currrently operates through his consultancy, Numedicus Ltd, having worked in drug repurposing for 15 years. Previously he was CEO of Arachnova, and prior to that held various senior positions in pharmaceutical drug discovery at GSK and Napp Research Centre. He has written widely on drug discovery strategy, and is the author of 70 published papers and patents.